跳至主要内容
临床试验/ITMCTR2100004509
ITMCTR2100004509招募中未知

Effectiveness and safety of a kind of Chinese herbal medicine compound combination in the treatment of portal hypertensive gastropathy in cirrhosis:protocol for a clinical study

Kailuan General Hospital, Tangshan, Hebei0 个研究点开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • (1) Comply with the diagnostic standards of Western medicine PHG in cirrhosis.
  • (2) The age is between 18-75 years old.
  • (3) Patients with no or small ascites, no upper gastrointestinal bleeding and hepatic encephalopathy.
  • (4) In the near future, people who take vasoactive drugs such as cardiotonic, nifedipine, nitrates and diuretics need to stop drugs for more than one week, and then observe the indexes after stabilization.
  • (5) Those who have voluntarily signed the informed consent.

排除标准

  • (1) Patients with severe diseases such as malignant hypertension, severe arrhythmia, acute myocardial infarction, cerebrovascular accident, etc.
  • (2) Patients with acute infection, trauma, surgery, diabetic ketoacidosis, and hyperosmolar coma recently.
  • (3) Patients with severe primary diseases such as brain, liver, kidney and hematopoietic system, mental illness and cognitive dysfunction.
  • (4) Patients with tumor and other organ failure.

研究者

发起方
Kailuan General Hospital, Tangshan, Hebei

相似试验